Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

5.09
+0.17003.46%
Post-market: 5.110.0200+0.39%19:04 EDT
Volume:1.69M
Turnover:8.58M
Market Cap:469.18M
PE:-4.55
High:5.17
Open:4.93
Low:4.93
Close:4.92
Loading ...

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

GlobeNewswire
·
26 Apr

Leerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)

TIPRANKS
·
22 Apr

Myriad Genetics Announces Study Results Show Patients With Depression Had Fewer Psychiatric Hospitalizations After Genesight Testing

THOMSON REUTERS
·
22 Apr

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

GlobeNewswire
·
22 Apr

Myriad Genetics Is Maintained at Buy by Goldman Sachs

Dow Jones
·
18 Apr

Myriad Genetics Inc : TD Cowen Cuts Target Price to $11 From $16

THOMSON REUTERS
·
16 Apr

Myriad Genetics Cut to Neutral From Buy by Guggenheim

Dow Jones
·
09 Apr

Guggenheim Downgrades Myriad Genetics to Neutral From Buy

MT Newswires Live
·
09 Apr

Press Release: Myriad Genetics Announces Inducement Awards

Dow Jones
·
09 Apr

BRIEF-Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer

Reuters
·
07 Apr

Press Release: Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Dow Jones
·
07 Apr

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

THOMSON REUTERS
·
07 Apr

Myriad Genetics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
01 Apr

Myriad Genetics price target lowered to $20 from $24 at Scotiabank

TIPRANKS
·
01 Apr

Myriad Genetics (MYGN) Receives a Buy from Scotiabank

TIPRANKS
·
01 Apr

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

Zacks
·
28 Mar

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Zacks
·
26 Mar

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory
·
17 Mar

Myriad Genetics Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $12.5 From $11.5

THOMSON REUTERS
·
12 Mar

Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley

TIPRANKS
·
12 Mar